TxCell SA, a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, has completed the development of its first-generation production process for its CAR-Treg technology. The process will be transferred to a contract manufacturing organization (CMO) for first-in-man clinical trials. For its first CAR-Treg manufacturing process, TxCell has isolated a subset of Treg cells that have shown to be stable and to display a strong a...